Journal
CURRENT DRUG METABOLISM
Volume 10, Issue 4, Pages 420-432Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920009788498978
Keywords
CYP-enzyme induction; drug-drug interactions; in vitro - in vivo extrapolation; modelling and simulation; quantitative pharmacology; pharmacokinetics; enzyme turn-over
Ask authors/readers for more resources
Although CYP induction is not generally considered to be as clinically relevant as CYP inhibition, there are important examples where induction has caused both therapeutic failure, due to insufficient exposure to parent drug, and toxicity, mediated by increased formation of reactive metabolites. Furthermore, while there has been considerable progress in the extrapolation of in vitro data to predict the in vivo consequences of enzyme inhibition, less attention has been given to the quantitative impact of enzyme induction as a mechanism of drug-drug interaction (DDI) and as a component of compound selection and early drug development. We discuss current approaches in the context of a mechanistic framework for the prediction of the extent and time-course of enzyme induction in vivo based on in vitro experimentation. Factors influencing the extent of DDI due to CYP induction are summarised, and areas deficient in information that would allow more accurate prediction within target populations are highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available